Pravastatin inhibits pro-inflammatory effects of Alzheimer's peptide Aβ1-42 in glioma cell culture in vitro

Pharmacological Research

Volumn 47, Issue 2, 2003, Pages 119-126

  Sun, Yong Xin ^a   Crisby, Milita ^b   Lindgren, Stefan ^a   Janciauskiene, Sabina ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Alzheimer's disease; Alzheimer's peptide; Inflammation; Pravastatin

Indexed keywords

CYTOKINE; FREE RADICAL; INTERLEUKIN 6; METALLOPROTEINASE; PEPTIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PRAVASTATIN; PROTEIN ALPHABETA 1 42; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; CELL ACTIVATION; CELL ASSAY; CELL CULTURE; CELL STIMULATION; CONTROLLED STUDY; DRUG EFFECT; DRUG TARGETING; ENZYME INDUCTION; GLIOMA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLAMMATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; TIME;

EID: 0037331420     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-6618(02)00288-8     Document Type: Article

References (55)

1. Siperstein M.D. Role of cholesterogenesis and isoprenoid synthesis in DNA replication and cell growth. J. Lipid Res. 25:1985;1462-1468.
2. Ginsberg H.N. Effects of statins on triglyceride metabolism. Am. J. Cardiol. 81:1998;32B-35B.
3. Bellosta S., Ferri N., Bernini F., Paoletti R., Corsini A. Non-lipid-related effects of statins. Ann. Med. 32:2000;164-176.
4. Osamah H., Mira R., Sorina S., Shlomo K., Michael A. Reduced platelet aggregation after fluvastatin therapy is associated with altered platelet lipid composition and drug binding to the platelets. Br. J. Clin. Pharmacol. 44:1997;77-83.
5. Koh K.K. Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability. Cardiovasc. Res. 47:2000;648-657.
6. Koga T., Kikuchi T., Miyazaki A., Koike H. Tissue-selective inhibition of sterol synthesis in mice by pravastatin sodium after a single or repeated oral administrations. Lipids. 30:1995;775-779.
7. Desager J.P., Horsmans Y. Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. Clin. Pharmacokinet. 31:1996;348-371.
8. Grip O., Janciauskiene S., Lindgren S. Pravastatin down-regulates inflammatory mediators in human monocytes in vitro. Eur. J. Pharmacol. 410:2000;83-92.
9. Crisby M., Fredriksson-Norden G., Shah P.K., Yano J., Zhu J., Nilsson J. Pravastatin content increases collagen content and decreases lipid content, inflammation, metalloproteinases and cell death in human carotid plaques: implications for plaque stabilization. Circulation. 103:2001;919-926.
10. Inoue I., Goto S., Mizotani K., Awata T., Mastunaga T., Kawai S.et al. Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of MRNA levels for interleukin-1beta, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor alpha (PPARalpha) in primary endothelial cells. Life Sci. 67:2000;863-876.
11. Bishop-Bailey D. Peroxisome proliferator-activated receptors in the cardiovascular system. Br. J. Pharmacol. 129:2000;823-834.
12. Pineda Torra I., Gervois P., Staels B. Peroxisome proliferator-activated receptor alpha in metabolic disease, inflammation, atherosclerosis and aging. Curr. Opin. Lipidol. 10:1999;151-159.
13. Lukiw W.J., Bazan N.G. Neuroinflammatory signaling upregulation in Alzheimer's disease. Neurochem. Res. 25:2000;1173-1184.
14. Styren S.D., Kamboh M.I., DeKosky S.T. Expression of differential immune factors in temporal cortex and cerebellum: the role of alpha-1-antichymotrypsin, apolipoprotein E, and reactive glia in the progression of Alzheimer's disease. J. Comp. Neurol. 396:1998;511-520.
15. Akiyama H., Ikeda K., Kondo H., McGeer P.L. Thrombin accumulation in brains of patients with Alzheimer's disease. Neurosci. Lett. 146:1992;152-154.
16. McGeer P.L., Rogers J. Anti-inflammatory agents as a therapeutic approach to Alzheimer's disease. Neurology. 42:1992;447-449.
17. Aisen P.S. Inflammation and Alzheimer's disease: mechanisms and therapeutic strategies. Gerontology. 43:1997;143-149.
18. Chan K.A., Andrade S.E., Boles M., Buist D.S., Chase G.A., Donahue J.G.et al. Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women. Lancet. 355:2000;2185-2188.
19. Jick H., Zornberg G.L., Jick S.S., Seshadri S., Drachman D.A. Statins and the risk of dementia. Lancet. 356:2000;1627-1631.
20. Fassbender K., Simons M., Bergmann C., Stroick M., Lutjohann D., Keller P.et al. Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc. Natl. Acad. Sci. U.S.A. 98:2001;5856-5861.
21. Bayer T.A., Wirths O., Majtenyi K., Hartmann T., Multhaup G., Beyreuther K.et al. Key factors in Alzheimer's disease: beta-amyloid precursor protein processing, metabolism and intraneuronal transport. Brain Pathol. 11:2001;1-11.
22. Tomita S., Kirino Y., Suzuki T. Cleavage of Alzheimer's amyloid precursor protein (APP) by secretases occurs after O-glycosylation of APP in the protein secretory pathway. Identification of intracellular compartments in which APP cleavage occurs without using toxic agents that interfere with protein metabolism. J. Biol. Chem. 273:1998;6277-6284.
23. Mattson M.P. Free radicals and disruption of neuronal ion homeostasis in AD: a role for amyloid beta-peptide? Neurobiol. Aging. 16:1995;679-682.
24. Howlett D.R., Jennings K.H., Lee D.C., Clark M.S., Brown F., Wetzel R.et al. Aggregation state and neurotoxic properties of Alzheimer beta-amyloid peptide. Neurodegeneration. 4:1995;23-32.
25. Bohrmann B., Tjernberg L., Kuner P., Poli S., Levet-Trafit B., Näslund J.et al. Endogenous proteins controlling amyloid β-peptide polymerization. Possible implications for β-amyloid formation in the central nervous system and in peripheral tissues. J. Biol. Chem. 274:1999;15990-15995.
26. 1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. U.S.A. 95:1998;6448-6453.
27. Carlson J., Eriksson S., Alm R., Kjellstrom T. Biosynthesis of abnormally glycosylated alpha 1-antitrypsin by a human hepatoma cell line. Hepatology. 4:1984;235-241.
28. Keidar S., Aviram M., Maor I., Oiknine J., Brook J.G. Pravastatin inhibits cellular cholesterol synthesis and increases low density lipoprotein receptor activity in macrophages: in vitro and in vivo studies. Br. J. Clin. Pharmacol. 38:1994;513-519.
29. Dichtl W., Moraga F., Ares M.P., Crisby M., Nilsson J., Lindgren S.et al. The carboxyl-terminal fragment of alpha1-antitrypsin is present in atherosclerotic plaques and regulates inflammatory transcription factors in primary human monocytes. Mol. Cell Biol. Res. Commun. 4:2000;50-61.
30. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurements with folin phenol reagents. J. Biol. Chem. 193:1951;265-275.
31. McGeer P.L., McGeer E., Rogers J., Sibley J. Anti-inflammatory drugs and Alzheimer's disease. Lancet. 335:1990;1037.
32. Veld B.A., Launer L.J., Hoes A.W., Ott A., Hofman A., Breteler M.M.et al. NSAIDs and incident Alzheimer's disease. The Rotterdam study. Neurobiol. Aging. 19:1998;607-611.
33. Combs C.K., Johnson D.E., Karlo J.C., Cannady S.B., Landreth G.E. Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. J. Neurosci. 20:2000;558-567.
34. Sun Y.X., Wright H.T., Janciauskiene S. Alpha1-antichymotrypsin/Alzheimer's peptide Abeta(1-42) complex perturbs lipid metabolism and activates transcription factors PPARgamma and NFkappaB in human neuroblastoma (Kelly) cells. J. Neurosci. Res. 67:2002;511-522.
35. El-Agnaf O.M., Mahil D.S., Patel B.P., Austen B.M. Oligomerization and toxicity of beta-amyloid-42 implicated in Alzheimer's disease. Biochem. Biophys. Res. Commun. 273:2000;1003-1007.
36. Hartley D.M., Walsh D.M., Ye C.P., Diehl T., Vasquez S., Vassilev P.M.et al. Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J. Neurosci. 19:1999;8876-8884.
37. Backstrom J.R., Miller C.A., Tökés Z.A. Characterization of neutral proteinases from Alzheimer-affected and control brain specimens: identification of calcium-dependent metalloproteinases from the hippocampus. J. Neurochem. 58:1992;983-992.
38. Sekine-Aizawa Y., Hama E., Watanabe K., Tsubuki S., Kanai-Azuma M., Kanai Y.et al. Matrix metalloproteinase (MMP) system in brain: identification and characterization of brain-specific MMP highly expressed in cerebellum. Eur. J. Neurosci. 13:2001;935-948.
39. Deb S., Gottschall P.E. Increased production of matrix metalloproteinases in enriched astrocyte and mixed hippocampal cultures treated with beta-amyloid peptides. J. Neurochem. 66:1996;1641-1647.
40. Backstrom J.R., Lim G.P., Cullen M.J., Tokes Z.A. Matrix metalloproteinase-9 (MMP-9) is synthesized in neurons of the human hippocampus and is capable of degrading the amyloid-beta peptide (1-40). J. Neurosci. 16:1996;7910-7919.
41. Akama K.T., Van Eldik L.J. Beta-amyloid stimulation of inducible nitric-oxide synthase in astrocytes is interleukin-1beta- and tumor necrosis factor-alpha (TNFalpha)-dependent, and involves a TNFalpha receptor-associated factor- and NFkappaB-inducing kinase-dependent signaling mechanism. J. Biol. Chem. 275:2000;7918-7924.
42. Strohmeyer R., Rogers J. Molecular and cellular mediators of Alzheimer's disease inflammation. J. Alzheimer Dis. 3:2001;131-157.
43. Griffin W.S., Sheng J.G., Royston M.C., Gentleman S.M., McKenzie J.E., Graham D.I.et al. Glial-neuronal interactions in Alzheimer's disease: the potential role of a 'cytokine cycle' in disease progression. Brain Pathol. 8:1998;65-72.
44. Christen Y. Oxidative stress and Alzheimer's disease. Am. J. Clin. Nutr. 71:2000;621S-629S.
45. Harris M.E., Hensley K., Butterfield D.A., Leedle R.A., Carney J.M. Direct evidence of oxidative injury produced by the Alzheimer's beta-amyloid peptide (1-40) in cultured hippocampal neurons. Exp. Neurol. 131:1995;193-202.
46. Varadarajan S., Yatin S., Aksenova M., Butterfield D.A. Review: Alzheimer's amyloid beta-peptide-associated free radical oxidative stress and neurotoxicity. J. Struct. Biol. 130:2000;184-208.
47. Kaltschmidt B., Uherek M., Volk B., Baeuerle P.A., Kaltschmidt C. Transcription factor NF-kappaB is activated in primary neurons by amyloid beta peptides and in neurons surrounding early plaques from patients with Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 94:1997;2642-2647.
48. Chinetti G., Fruchart J.C., Staels B. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm. Res. 49:2000;497-505.
49. Kitamura Y., Shimohama S., Koike H., Kakimura J., Matsuoka Y., Nomura Y.et al. Increased expression of cyclooxygenases and peroxisome proliferator-activated receptor-gamma in Alzheimer's disease brains. Biochem. Biophys. Res. Commun. 254:1999;582-586.
50. Combs C.K., Johnson D.E., Karlo J.C., Cannady S.B., Landreth G.E. Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. J. Neurosci. 20:2000;558-567.
51. Rohn T.T., Wong S.M., Cotman C.W., Cribbs D.H. 15-Deoxy-delta-12,14-prostaglandin J2, a specific ligand for peroxisome proliferator-activated receptor-gamma, induces neuronal apoptosis. Neuroreport. 12:2001;839-843.
52. Rogers J., Lue L-F. Microglia chemotaxis, activation, and phagocytosis of amyloid β-peptide as linked phenomena in Alzheimer's disease. Neurochem. Int. 39:2001;333-340.
53. Lue L-F., Walker D.G., Rogers J. Modeling microlial activation in Alzheimer's disease with human postmorten microglia cultures. Neurobiol. Aging. 22:2001;945-956.
54. Liu Y., Qin L., Wilson B.C., An L., Hong J-S., Liu B. Inhibition by naloxone stereoisomers of β-amyloid peptide (1-42)-induced superoxide production in micriglia and degeneration of cortical and mesencephalic neurons. J. Pharmacol. Exp. Ther. 302:2002;1212-1219.
55. Kilgore M.W., Tate P.L., Rai S., Sengoku E., Price T.M. MCF-7 and T47D human breast cancer cells contain a functional peroxisomal response. Mol. Cell Endocrinol. 129:1997;229-235.